Novo Nordisk launches fast-acting insulin drug Fiasp, in Canada

27 March 2017

Danish pharmaceutical company Novo Nordisk (NOV: N) has announced that its new fast-acting mealtime insulin Fiasp (insulin aspart) has been launched in Canada, the first market for the product.

Fiasp was developed with the aim of achieving faster initial absorption, to improve glycemic control after a meal, in people with type 1 and type 2 diabetes.

The company says that, in clinical trials, the drug showed improved overall glycemic control in type 1 diabetes and comparable overall glycemic control in type 2 diabetes, compared with the company’s other insulin therapy NovoRapid (insulin apart).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK